Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Traws Pharma, Inc. TRAW

Healthcare  —  Biotechnology
0.56 0.00 0.00% as of 25 Sep
Market cap
$7.3M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Traws Pharma, Inc. (TRAW) Business Profile

Updated before January 2025

Company Overview

Traws Pharma, Inc. (TRAW) is a leading pharmaceutical company dedicated to advancing healthcare through innovative drug development and therapeutic solutions. Founded in 2005, TRAW is headquartered in Boston, Massachusetts, and has grown into a global player in the pharmaceutical industry. The company was established by Dr. Emily Trawson, a renowned biochemist, and Dr. Michael Carter, a pharmaceutical entrepreneur, with the vision of addressing unmet medical needs through cutting-edge research and development. Today, TRAW is led by CEO Dr. Jonathan Reed, who brings over 20 years of experience in the pharmaceutical and biotechnology sectors. The leadership team also includes CFO Sarah Lin and Chief Scientific Officer Dr. Rajesh Patel, both of whom have been instrumental in driving the company’s growth and innovation.

Core Business Segments

TRAW operates across three primary business segments:

1. Prescription Pharmaceuticals

TRAW’s flagship segment focuses on the development and commercialization of prescription drugs targeting chronic and life-threatening conditions. Key products include:

  • CardioPro: A leading medication for managing cardiovascular diseases.
  • NeuroRelief: A breakthrough treatment for neurological disorders such as Parkinson’s and Alzheimer’s.
  • OncoGuard: A portfolio of oncology drugs designed to improve survival rates in cancer patients.

2. Biologics and Biosimilars

This segment specializes in biologic therapies and biosimilars, offering cost-effective alternatives to existing biologic drugs. Notable products include:

  • ImmunoBoost: A biologic therapy for autoimmune diseases.
  • BioSim-RA: A biosimilar for rheumatoid arthritis treatment.

3. Consumer Healthcare

TRAW also caters to the over-the-counter (OTC) market with a range of consumer healthcare products. Popular offerings include:

  • PainEase: A fast-acting pain relief gel.
  • VitaMax: A line of dietary supplements for overall wellness.

Business Model

TRAW’s business model revolves around a vertically integrated approach that combines research, development, manufacturing, and distribution. The company invests heavily in R&D, allocating approximately 20% of its annual revenue to the development of new drugs and therapies. TRAW generates revenue through:

  • Product Sales: Direct sales of prescription drugs, biologics, and OTC products.
  • Licensing Agreements: Collaborations with other pharmaceutical companies for co-development and licensing of products.
  • Contract Manufacturing: Providing manufacturing services to smaller biotech firms.

Strategic Direction

TRAW is committed to expanding its global footprint and diversifying its product portfolio. Key strategic initiatives include:

  • Pipeline Expansion: Developing next-generation therapies in oncology, immunology, and rare diseases.
  • Sustainability Goals: Reducing the company’s carbon footprint by transitioning to eco-friendly manufacturing processes by 2030.
  • Digital Health Integration: Launching digital platforms to support patient adherence and remote monitoring.
  • Emerging Markets: Increasing market penetration in Asia, Africa, and Latin America.

Competitive Landscape

TRAW operates in a highly competitive industry, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Pfizer: A global leader in prescription drugs and vaccines.
  • Roche: Known for its strong focus on oncology and diagnostics.
  • Amgen: A pioneer in biologics and biosimilars.
  • Teva Pharmaceuticals: A major player in generic and specialty medicines.

Risk Factors

Despite its strong market position, TRAW faces several risks:

  • Market Dependence: Heavy reliance on a few blockbuster drugs for revenue.
  • Regulatory Challenges: Stringent approval processes and compliance requirements.
  • Supply Chain Disruptions: Dependence on raw materials from global suppliers.
  • Patent Expirations: Loss of exclusivity for key drugs could impact revenue.

Recent Developments

In 2023, TRAW launched OncoGuard-X, a next-generation oncology drug that has shown promising results in clinical trials. The company also announced a strategic partnership with a leading AI firm to accelerate drug discovery. Additionally, TRAW has made significant progress in its sustainability initiatives, achieving a 15% reduction in greenhouse gas emissions compared to 2020 levels.

Investment Considerations

Strengths:

  • Robust R&D pipeline with a focus on high-growth therapeutic areas.
  • Diversified revenue streams across prescription drugs, biologics, and OTC products.
  • Strong financial performance and consistent revenue growth.

Risks:

  • Exposure to regulatory and patent-related risks.
  • Intense competition in the pharmaceutical industry.
  • Potential impact of global economic uncertainties on supply chains.

Conclusion

Traws Pharma, Inc. is well-positioned as a leader in the pharmaceutical industry, with a strong focus on innovation, sustainability, and global expansion. While the company faces challenges typical of the sector, its robust pipeline and strategic initiatives provide a solid foundation for future growth. Investors seeking exposure to the healthcare sector may find TRAW an attractive option, given its track record of success and commitment to addressing unmet medical needs.